Extensive Macular Atrophy with Pseudodrusen: a Differential Diagnosis of Age-Related Retinal Dystrophy

Vol 1, 2023 - 166323
Oral (On site Format)
Favorite this paper
How to cite this paper?
Abstract

Introduction: retinal atrophy with pseudodrusen appearance (EMAP) is a progressive ocular disease, akin to AMD, affecting the retina. Although AMD is more common in the elderly, EMAP can occur in young individuals and be hereditary. Characterized by pseudodrusen, small yellowish round lesions in the retina, it leads to degeneration and central vision loss, similar to AMD. While its underlying mechanisms aren't fully clarified, genetic and environmental factors play a significant role in its development. Advancements in imaging technology, including optical coherence tomography (OCT), have improved understanding of its pathology and facilitated early diagnosis. Objectives: This paper aims to report a case of extensive macular atrophy with pseudodrusen appearance and its repercussions. Methods: I.F.D.C, a 44-year-old female with 2 children from Guarulhos-SP, was referred to a retina specialist in June 2022 for retinal dystrophy investigation. The patient had a previous diagnosis of early drusen at 26 years during routine checkups and remained asymptomatic until that point. Results: During the consultation, the patient complained of bilateral central scotomas, starting on the right side 9 months prior and on the left side 4 months prior. No significant personal history or autoimmune diseases were reported, although there was a maternal history of AMD at 60 years old. Fundus examination revealed Golden Sheen in the mid-periphery, signs of macular atrophy, and small central drusen bilaterally. Further complementary exams were pursued. Conclusion: EMAP is an ophthalmologic disease with loosely defined diagnostic criteria, characterized by early onset, symmetrical bilateral macular atrophy, foveal involvement, and stone-pavement-like degeneration. Studies suggest that biological, genetic, environmental, and dietary factors may be associated with the disease, with higher prevalence in women and patients with a family history of glaucoma and AMD, as well as in areas with high industrialization and exposure to toxic substances. The patient's history and clinical presentation, despite lacking stone-pavement-like degeneration in the periphery, align with the disease's findings. EMAP patients under 50 years old experience rapid atrophy progression with a larger vertical diameter and no typical drusen formation. Identifying the pathology is important to prevent confusion with AMD or early drusen in younger patients. However, there is currently no available treatment, and the lack of genetic mapping is a constraint for developing specific therapies for the condition

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Centro Universitário Padre Albino (UNIFIPA)
  • 2 Universidade de São Paulo
  • 3 Universidade Federal de São Paulo
Track
  • 1. Management of diseases and immune response: inflammatory, infectious, non-infectious, autoimmune and lifestyle diseases
Keywords
DMRI; distrofias retinianas; genética; Oftalmologia; EMAP